

# CENTER FOR DRUG EVALUATION AND RESEARCH

**APPLICATION:NDA 50-744**

## CONTENTS

	Included	Pending Completion	Not Prepared	Not Required
<b>Approval Letter</b>	X			
<b>Tentative Approval Letter</b>				X
<b>Approvable Letter</b>			X	
<b>Final Printed Labeling</b>		X		
<b>Medical Review(s)</b>	X			
<b>Chemistry Review(s)</b>	X			
<b>EA/FONSI</b>	X			
<b>Pharmacology Review(s)</b>	X			
<b>Statistical Review(s)</b>	X			
<b>Microbiology Review(s)</b>	X			
<b>Clinical Pharmacology Biopharmaceutics Review(s)</b>	X			
<b>Bioequivalence Review(s)</b>			X	
<b>Administrative Document(s)</b>	X			
<b>Correspondence</b>	X			

Dr. Reddy's Laboratories, Ltd., et al.  
v.  
Galderma Laboratories, Inc.  
IPR2015-\_\_\_\_\_

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**Approval Package for:**

**Application Number: NDA 50-744**

**Trade Name: PERIOSTAT CAPSULES, 20 MG**

**Generic Name:(doxycycline hyclate USP)**

**Sponsor:CollaGenex Pharmaceuticals, Inc.**

**Approval Date: September 30, 1998**

**INDICATION: Provides for the use of Periostat (doxycycline hyclate USP) Capsules, 20 mg as an adjunct to subgingival scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis.**

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**Application Number: NSA 50-744**

**APPROVAL LETTER**



NDA 50-744

SEP 30 1998

CollaGenex Pharmaceuticals, Inc.  
Attention: Christopher Powala  
Director, Drug Development and Regulatory Affairs  
301 South State Street  
Newtown, PA 18940

Dear Mr. Powala:

Please refer to your new drug application (NDA) dated August 30, 1996, received August 30, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Periostat™ (doxycycline hyclate USP) Capsules, 20 mg. We note that this application is subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

We acknowledge receipt of your submissions dated August 28, October 1, November 13, December 8, 1997; January 6, 14, and 19, February 10, March 2, 18, and 31, April 23 and 28, July 9 and 29, and September 3, 14, 16, 22, 24 (2), and 25, 1998. Your submission of March 31, 1998 constituted a full response to our August 27, 1997, action letter. The user fee goal date for this application is October 1, 1998.

This new drug application provides for the use of Periostat™ (doxycycline hyclate USP) Capsules, 20 mg as an adjunct to subgingival scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed labeling text. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, immediate container and carton labels). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug. We acknowledge your commitment made in the teleconference with this Division on September 16, 1998, to revise the carton and container labeling so that the prominence of the established name and tradename is commensurate and in accordance with 21 CFR 201.10(g)(2).

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved NDA 50-744". Approval of this submission by FDA is not required before the labeling is used.

NDA 50-744

Page 2

We remind you of your Phase 4 commitments agreed to in your submissions dated August 3, 1998, and September 14, 1998. These commitments, respectively, are listed below:

Protocols, data, and final reports should be submitted to your IND for this product and a copy of the cover letter sent to this NDA. If an IND is not required to meet your Phase 4 commitments, please submit protocols, data and final reports to this NDA as correspondence. In addition, under 21 CFR 314.82(b)(2)(vii), we request that you include a status summary of each commitment in your annual report to this NDA. The status summary should include the number of patients entered in each clinical study, expected completion and submission dates, and any changes in plans since the last annual report. For administrative purposes, all submissions, including labeling supplements, relating to these Phase 4 commitments must be clearly designated "Phase 4 Commitments".

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.